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ABSTRACT
Background: Pediatric bipolar I disorder (BP-I) and childhood schizophrenia (SZ) share cer-
tain symptoms (e.g., psychosis, aggression/irritability [A/I]), and the psychotic and A/I fea-
tures are treated with neuroleptics in both disorders. Thus, it is of interest to examine the as-
sociation of GAD1 to child BP-I because of its recently reported association to childhood SZ.
Methods: Child BP-I probands were obtained by consecutive new case ascertainment, and
the phenotype was defined as current DSM-IV BP-I (manic or mixed phase) with at least one
of the cardinal symptoms of mania (i.e., elation and/or grandiosity) and a Children’s Global
Assessment Scale score 60 (clinical impairment). These child BP-I probands are part of a
large, ongoing, longitudinal study in which the phenotype has been validated by unique
symptoms, longitudinal stability, and 7–8 times greater family loading than adult BP-I
probands. Genotyping was performed using a TaqMan® Validated SNP Genotyping Assay,
and FBAT was used for analysis.
Results: There were 48 families. The rs2241165 A allele was preferentially transmitted (FBAT
2  5.2, df  1, p  0.022). No interaction between this GAD1 SNP and the Val66 BDNF al-
lele was found.
Conclusions: These data are consistent with some shared genetic vulnerability between child
BP-I and SZ, which may be related to similar treatments.
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INTRODUCTION
PEDIATRIC BIPOLAR I disorder (BP-I) and child-hood schizophrenia (SZ) share certain
symptoms (e.g., psychosis, aggression/irri-
tability [A/I]) (Kumra et al. 1996; Geller et al.
2002a; Kowatch et al. 2005; Tillman and Geller,
in press; Tillman et al., 2008), and the psychotic
and A/I features are treated with neuroleptics
in both disorders (Kumra et al. 1996; DelBello
et al. 2002, 2006; Shaw et al. 2006). Thus, it is of
interest to examine the relationship of GAD1
single nucleotide polymorphism (SNP) in pe-
diatric BP-I, because four correlated SNPs (r2 
0.92) were found to be associated with child-
hood SZ (Addington et al. 2005). In addition,
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the GAD1 gene is of interest for child BP-I 
because of decreased expression of GAD67
(which is encoded by the GAD1 gene) in post-
mortem brains of BP adults (Guidotti et al.
2000; Knable et al. 2001; Heckers et al. 2002;
Woo et al. 2004; Fatemi et al. 2005; Torrey et al.
2005). There are also two linkage studies (Ci-
chon et al. 2001; Ewald et al. 2003) and one as-
sociation study (Lundorf et al. 2005) that pro-
vide some suggestion of a relationship between
GAD1 and BP in adults. Recently, Benes et al.
(2007) reported down regulation of GAD67 in
the hippocampus of BP subjects, further sup-
porting study of this gene in a child BP popu-
lation.
The GAD1 gene on chromosome 2q31 en-
codes for the GAD67 protein that is responsi-
ble for decarboxylation of glutamate and is ex-
pressed primarily in the brain (Bu and Tobin
1994). Glutamic acid decarboxylase is an en-
zyme that catalyzes the decarboxylation of glu-
tamate to GABA and is present in GABA neu-
rons in the brain.
METHODS AND MATERIALS
Child BP-I probands are part of the large, on-
going, NIMH-funded, longitudinal “Phenome-
nology and Course of Pediatric Bipolar Disor-
ders” study, in which the phenotype has been
validated by unique symptoms, longitudinal
stability, and 7-8 times greater familiality than
adult BP-I probands (Geller et al. 2002a, 2002b,
2002c, 2004a, 2006; Geller and Tillman 2005).
The phenotype was defined as current DSM-IV
BP-I (manic or mixed phase) with at least one
of the cardinal symptoms of mania (i.e., elation
and/or grandiosity) and a Children’s Global
Assessment Scale (CGAS) (Shaffer et al. 1983)
score 60, to establish clinical impairment in
the moderate and severe ranges (Bird et al.
1992; Geller et al. 2002a). Cardinal symptoms
are those that occur only in a single disorder.
By way of analogy, DSM-IV requires sad mood
or anhedonia for major depressive disorder.
Using cardinal symptoms avoided diagnosing
mania only by symptoms that overlapped with
those for attention-deficit/hyperactivity disor-
der (ADHD) (e.g., irritability, hyperactivity,
distractibility).
Probands were obtained by consecutive new
case ascertainment from designated pediatric
and child psychiatry facilities (Geller et al.
2002a). To enhance generalization, probands
were obtained from pediatric and child psy-
chiatry sites by consecutive new case ascer-
tainment, between 1995 and 1998 (Geller et al.
2002a). In this schema, every new case at the
designated facilities was screened for exclu-
sions (e.g., major medical illness), and those
still eligible were interviewed by telephone,
e.g., a child with a sore throat was given the
same screening as a child with hyperactivity.
Cases that were still not excluded after the ini-
tial telephone contact were given the complete
research assessment (Geller et al. 2002a).
Subjects were assessed by experienced,
blinded research nurses with instruments in-
cluding the Washington University in St. Louis
Kiddie Schedule for Affective Disorders and
Schizophrenia (WASH-U-KSADS) (Geller et al.
2001). The WASH-U-KSADS was administered
separately to parents about their children and
to children about themselves (Tillman et al.
2004). The child BP-I phenotype was defined as
current DSM-IV BP-I (manic or mixed phase)
with at least one of the two cardinal symptoms
of mania (i.e., elation and/or grandiosity)
(Geller et al. 2002a).
Informed consent was obtained from the par-
ents and assent from the child. The study and
consent forms were approved by the Wash-
ington University in St. Louis Human Studies
Committee. Consents for genetic studies at
Washington University in St. Louis are for all
future genetic studies.
All laboratory procedures were performed
blind to all clinical information, including fam-
ily relationship. DNA extraction was per-
formed by using the PureGene DNA extraction
kit (Gentra Systems,Minneapolis, MN). For
normalization of DNA concentration across the
384 well plate, DNA quantitation was con-
ducted with the Quant-iT™ PicoGreen® ds-
DNA Assay Kit by Molecular Probes, Inc. (Eu-
gene, OR). rs2241165 was selected because the
A allele tagged the overtransmitted haplotype
consisting of four associated SNPs in complete
LD (r2  0.92 between rs2241165 and the other
associated SNPs) in the childhood SZ study
(Addington et al. 2005). SNP genotyping of
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rs2241165 was performed by using a TaqMan®
Validated SNP Genotyping Assay (Applied
Biosystems, Foster City, CA). Data acquisition
was performed on the Fluoroskan Ascent
(Thermo Electron Corporation, Waltham, MA)
by using dual measurement of fluorescence in-
tensity for VIC and FAM labeled probes.
Thirty-one samples were rerun in a separate as-
say on a separate day and all duplicate calls
were concordant.
Family Based Association Test (FBAT) soft-
ware (http://www.biostat.harvard.edu/fbat/
fbat.htm) was used to analyze GAD1 genotype
data. FBAT tests for preferential transmission
of an allele to affected offspring. The particu-
lar SNP tested was rs2241165, which is the 
SNP that was associated with childhood SZ
(Addington et al. 2005). Previously, the brain-
derived neurotrophic factor (BDNF) Val66Met
polymorphism was found to be in linkage dis-
equilibrium in our child BP-I sample (Geller et
al., 2004b). Logistic regression models were
used to test for an interaction between the
BDNF and GAD1 alleles.
RESULTS
There were 55 probands with GAD1
rs2241165 SNP genotype data. This included 2
sibling pairs, so genotype data was available
for 53 independent families. One family was
not included in the analysis, because of a par-
ent-child incompatibility. In this family, both
parents were genotyped as having two A alle-
les, but the child was heterozygous for
rs2241165. Four other families were not in-
cluded because of a missing genotype in one
family member. Therefore, FBAT analysis was
conducted on 48 families (including 2 families
with 2 probands). The overall call rate (i.e., the
number of genotype calls divided by all sam-
ples attempted) was 96.9%.
The 50 PEA-BP-I probands in these families
were aged 11.2 (SD  2.9), age of onset of base-
line mania episode was 7.9 (SD  3.9), duration
of baseline mania episode was 3.2 (SD  2.6)
years, and baseline CGAS was 43.4 (SD  8.0).
Female subjects comprised 40.0% of the sam-
ple, 54.0% were prepubertal, 88.0% were Cau-
casian, 2.0% were black, 2.0% were Hispanic,
and 8.0% were of some other race.
Frequency of parental A alleles was 70.3%.
This is consistent with the frequency of
rs2241165 A alleles in the general Caucasian
population (70.0%) (http://www.ncbi.nlm.
nih.gov/SNP/snp_ss.cgi?subsnp_id4419998
3). Proband and parental genotypes were in
Hardy-Weinberg equilibrium (HWE) (pro-
band: 2  0.3, df  1, p  0.569; parental: 2 
0.1, df  1, p  0.822).
The FBAT analyses showed preferential
transmission of the rs2241165 A allele (2  5.2,
df  1, p  0.022). As illustrated in Fig. 1, the
A allele was transmitted 29 times and not trans-
mitted 14 times from heterozygous parents,
giving an odds ratio of 2.07. The empirical level
of significance for this test using the Monte
Carlo method in FBAT was p  0.025. Addi-
tional FBAT analyses by proband sex, pubertal
status, and age of BP-I onset were not more sig-
nificant than the FBAT for the overall group.
No significant interaction was found be-
tween the GAD1 and BDNF alleles in this 
sample.
DISCUSSION
These results provide preliminary evidence
of association between the GAD1 SNP
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FIG. 1. GAD1 rs2241165 allele transmission in 48 fami-
lies (2 families included 2 probands). Of the 96 parents in
the 48 families, 41 were heterozygous for the GAD1
rs2241165 SNP (i.e., had one A and one G allele). Two of
these parents were part of families with two probands.
Shaded cells indicate transmission of alleles from het-
erozygous parents. Preferential transmission of rs2241165
A alleles to probands with a prepubertal and early ado-
lescent bipolar I disorder phenotype was supported 
(2  5.2, df  1, p  0.022).
rs2241165 and child onset BP-I. Because pref-
erential transmission of the same GAD1 SNP
rs2241165 A allele (and 3 highly correlated
SNPs) was also reported in a sample of child-
onset schizophrenia, this finding is not specific
to child BP (Addington et al. 2005), but is con-
sistent with the symptomatic (e.g., psychosis,
A/I) and treatment (e.g., neuroleptic) overlap
between these disorders. If replicated, these
data may suggest overlap in genetic vulnera-
bility between child BP-I and child onset SZ
that may be related to the use of neuroleptics
for both disorders (Kumra et al. 1996; DelBello
et al. 2002, 2006; Shaw et al. 2006). These find-
ings are consistent with other examples of vul-
nerability genes for both SZ and BP, e.g., the
DAOA gene has been implicated in both SZ
and BP (Detera-Wadleigh and McMahon 2006).
Limitations include small sample size, and
thus relatively low power. The selection of a sin-
gle SNP is logical because it was the best tagging
SNP being followed up from the previous study
of childhood schizophrenia. However, this SNP
would not be expected to be functional, and fur-
ther resequencing of the coding region and con-
served noncoding variation in future studies
would be necessary to identify functional varia-
tion. Future studies should consider genotyping
other polymorphisms within this region, includ-
ing those in Straub et al. (2007).
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